STOCK TITAN

Oragenics Stock Price, News & Analysis

OGEN NYSE

Company Description

Company Overview

Oragenics Inc (OGEN) is a publicly-traded biopharmaceutical company renowned for advancing a unique pipeline of proprietary technologies. The company focuses on the development and research of innovative pharmaceutical therapies in both neurology and infectious diseases, as well as breakthrough products in the field of oral health. With an emphasis on non-traditional drug delivery systems, Oragenics has established itself as a significant player in the clinical-stage biotechnology sector.

Innovative Technology and Product Pipeline

At the heart of Oragenics is its proprietary Probiora3 technology, which underpins a range of novel offerings. Among these is a new probiotic mint product designed to naturally support gum and tooth health while providing benefits such as breath freshening and tooth whitening. This product exemplifies the company’s commitment to revolutionizing oral health through innovative research and formulation techniques.

In addition, Oragenics is developing a groundbreaking intranasal delivery system that is engineered to facilitate rapid drug uptake into the brain. This technology is critical for their lead therapeutic candidate, a fully synthetic neurosteroid designed for the treatment of concussions. The formulation is lipophilic and able to cross the blood-brain barrier swiftly, targeting inflammation, oxidative stress, and swelling—an approach that is firmly rooted in advanced neuropharmacological principles.

Research and Development in Neurology and Infectious Diseases

The company’s robust R&D pipeline extends beyond oral health and encompasses therapeutic interventions for infectious diseases and neurological disorders. Through rigorous preclinical and clinical studies, Oragenics is addressing significant treatment gaps in conditions such as mild traumatic brain injury and other neurodegenerative challenges. Its research methodology integrates intranasal casting studies that simulate drug delivery within the nasal passage, a model that is accepted by regulatory agencies as a surrogate for human administration.

Market Position and Competitive Landscape

Oragenics operates in a competitive environment where innovation in drug delivery systems is paramount. The strategic integration of advanced diagnostic platforms with therapeutic interventions positions the company uniquely against traditional systemic drug delivery approaches. By focusing on rapid and targeted delivery, Oragenics aims to reduce systemic exposure while enhancing therapeutic outcomes, a differentiation that is increasingly valued in the biotech industry.

Operational Excellence and Industry Expertise

  • Technical Prowess: Leveraging deep expertise in pharmaceutical research, Oragenics uses innovative methods such as nanoparticle spray drying to enhance drug formulation and absorption.
  • Extensive Pipeline: With a comprehensive portfolio of candidates in various stages of development—from discovery to clinical trials—the company is well-positioned to address unmet medical needs across several therapeutic areas.
  • Regulatory Engagement: The utilization of FDA-accepted studies, such as intranasal casting, underscores the company’s commitment to rigorous scientific evaluation and regulatory compliance.

Scientific Rigor and Transparent Communication

Oragenics is committed to maintaining transparency in its research and development processes. By delivering detailed clinical and preclinical data, the company fosters trust among investors, healthcare professionals, and regulatory bodies. Its strategic communications emphasize evidence-based research, underscoring both the strengths and challenges inherent in bringing innovative therapies to market.

Conclusion

In summary, Oragenics stands as a paradigm of innovation in the biopharmaceutical sector. Through its pioneering work in intranasal drug delivery, advanced formulations, and a focused pipeline in neurology and infectious diseases, the company demonstrates both depth of research and a commitment to addressing critical health challenges. Its methodical, science-driven approach makes Oragenics a pivotal name to watch in the evolving landscape of biotechnology.

Stock Performance

$—
0.00%
0.00
Last updated:
-94.55 %
Performance 1 year
$3.8M
Market Cap
21.5M
Shares outstanding

SEC Filings

No SEC filings available for Oragenics.

Financial Highlights

$0
Revenue (TTM)
-$10,567,918
Net Income (TTM)
-$1.60
Diluted EPS (TTM)
-$8,597,382
Operating Cash Flow
0.87
Current Ratio
-$10,558,815
Operating Income

Upcoming Events

Frequently Asked Questions

What is the current stock price of Oragenics (OGEN)?

The current stock price of Oragenics (OGEN) is $0.1941 as of April 24, 2025.

What is the market cap of Oragenics (OGEN)?

The market cap of Oragenics (OGEN) is approximately 3.8M.

What is the revenue (TTM) of Oragenics (OGEN) stock?

The trailing twelve months (TTM) revenue of Oragenics (OGEN) is $0.

What is the net income of Oragenics (OGEN)?

The trailing twelve months (TTM) net income of Oragenics (OGEN) is -$10,567,918.

What is the earnings per share (EPS) of Oragenics (OGEN)?

The diluted earnings per share (EPS) of Oragenics (OGEN) is -$1.60 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Oragenics (OGEN)?

The operating cash flow of Oragenics (OGEN) is -$8,597,382.

What is the current ratio of Oragenics (OGEN)?

The current ratio of Oragenics (OGEN) is 0.87, indicating the company's ability to pay short-term obligations.

What is the operating income of Oragenics (OGEN)?

The operating income of Oragenics (OGEN) is -$10,558,815.

What is the core focus of Oragenics?

Oragenics is focused on developing innovative pharmaceutical therapies, particularly through intranasal delivery systems in the fields of neurology and infectious diseases, as well as advancing oral health solutions.

How does Oragenics develop its products?

The company employs proprietary technologies, such as Probiora3, combined with rigorous preclinical and clinical studies to design and evaluate novel product formulations and delivery systems.

What makes Oragenics' approach to drug delivery unique?

Oragenics utilizes an advanced intranasal delivery system that allows drugs to bypass traditional administration routes, enhancing rapid brain uptake and reducing systemic exposure.

Which therapeutic areas does Oragenics target?

The company targets multiple areas, including neurological disorders such as concussions and infectious diseases, as well as innovations in oral health through products like probiotic mints.

What is the significance of the intranasal casting studies?

Intranasal casting studies are essential for evaluating the bioavailability and distribution of formulations within the nasal cavity, providing supportive data for regulatory submissions.

How does Oragenics maintain regulatory standards in its research?

By implementing FDA-accepted methodologies and conducting comprehensive preclinical studies, Oragenics ensures its products meet strict regulatory criteria, underscoring its commitment to scientific rigor.

What are the competitive advantages of Oragenics in the biopharmaceutical market?

The company differentiates itself through its dual focus on innovative intranasal delivery for neurological applications and advanced oral health solutions, supported by a robust product pipeline and expert research.

How does Oragenics communicate its scientific research to stakeholders?

Oragenics emphasizes transparent reporting of clinical and preclinical findings, utilizing detailed documentation and studies to build trust with investors, regulatory bodies, and healthcare professionals.